NASDAQ:APRE - Aprea Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.40
  • Forecasted Upside: 338.71 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.65
▲ +0.2 (4.49%)
1 month | 3 months | 12 months
Get New Aprea Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APRE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APRE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$20.40
▲ +338.71% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Aprea Therapeutics in the last 3 months. The average price target is $20.40, with a high forecast of $45.00 and a low forecast of $6.00. The average price target represents a 338.71% upside from the last price of $4.65.
Hold
The current consensus among 6 polled investment analysts is to hold stock in Aprea Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/15/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/14/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2021Royal Bank of CanadaLower Price TargetSector Perform$10.00 ➝ $8.00High
i
3/17/2021Royal Bank of CanadaLower Price TargetSector Perform$10.00 ➝ $8.00High
i
12/29/2020Morgan StanleyLower Price Target$34.00 ➝ $6.00N/A
i
12/29/2020HC WainwrightReiterated RatingNeutral$30.00 ➝ $6.00N/A
i
12/29/2020Royal Bank of CanadaReiterated RatingHold$10.00N/A
i
12/28/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$40.00 ➝ $10.00N/A
i
12/28/2020Robert W. BairdDowngradeOutperform ➝ NeutralN/A
i
12/16/2020Morgan StanleyLower Price TargetEqual Weight$39.00 ➝ $34.00High
i
12/16/2020Berenberg BankInitiated CoverageBuy$37.00High
i
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralLow
i
8/12/2020HC WainwrightReiterated RatingHold$30.00High
i
Rating by A. Fein at HC Wainwright
6/22/2020HC WainwrightInitiated CoverageNeutral$30.00High
i
Rating by A. Fein at HC Wainwright
6/11/2020Royal Bank of CanadaReiterated RatingBuy$42.00High
i
4/20/2020Robert W. BairdInitiated CoverageOutperform$45.00Low
i
4/15/2020Morgan StanleyBoost Price TargetEqual Weight$36.00 ➝ $39.00Low
i
3/29/2020Royal Bank of CanadaReiterated RatingBuy$42.00Low
i
3/27/2020Morgan StanleyBoost Price TargetHold$23.00 ➝ $36.00High
i
10/28/2019Royal Bank of CanadaInitiated CoverageOutperform$33.00Medium
i
10/28/2019Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$23.00Medium
i
10/28/2019JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$23.00Medium
i
(Data available from 4/14/2016 forward)
Aprea Therapeutics logo
Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $4.65
$4.49
$4.66

50 Day Range

MA: $5.50
$4.42
$6.56

52 Week Range

Now: $4.65
$4.31
$41.12

Volume

1,866 shs

Average Volume

1,543,965 shs

Market Capitalization

$98.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Aprea Therapeutics?

The following sell-side analysts have issued research reports on Aprea Therapeutics in the last twelve months: Berenberg Bank, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for APRE.

What is the current price target for Aprea Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Aprea Therapeutics in the last year. Their average twelve-month price target is $20.40, suggesting a possible upside of 358.4%. Robert W. Baird has the highest price target set, predicting APRE will reach $45.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $6.00 for Aprea Therapeutics in the next year.
View the latest price targets for APRE.

What is the current consensus analyst rating for Aprea Therapeutics?

Aprea Therapeutics currently has 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in APRE, but not buy more shares or sell existing shares.
View the latest ratings for APRE.

What other companies compete with Aprea Therapeutics?

How do I contact Aprea Therapeutics' investor relations team?

Aprea Therapeutics' physical mailing address is 535 BOYLSTON STREET, BOSTON MA, 02116. The company's listed phone number is 609-510-4718 and its investor relations email address is [email protected] The official website for Aprea Therapeutics is www.aprea.com.